Roche Diagnostics and DuPont Pharmaceuticals Announce Co-Promotion Agreement for Anticoagulation Management Tools

Strategic Insights -

Roche Diagnostics and DuPont Pharmaceuticals Company have signed a five-year agreement to co-promote existing management tools that improve care for patients on anticoagulant therapy. DuPont Pharmaceuticals' oral anticoagulant Coumadin(R) (Warfarin Sodium Tablets, USP) Crystalline requires regular monitoring of the blood's ability to clot, a task made easier by the CoumaCare(SM) Process of Care, a systematic approach that combines patient management materials and a tracking software application. This comprehensive management support service helps improve patient outcomes, lower costs associated with adverse events, and enhance patient satisfaction.

Key Takeaways:

  • The co-promotion agreement is for a five-year period, focusing on existing management tools for anticoagulant therapy.
  • DuPont Pharmaceuticals' Coumadin(R) requires regular monitoring of the blood's ability to clot, measured by a prothrombin time test (International Normalized Ratio or INR).
  • The CoumaCare(SM) Process of Care, a systematic approach, combines patient management materials and a tracking software application to simplify patient management and improve patient compliance.
  • CoaguChek(TM), a portable instrument developed by Roche Diagnostics, offers a fast and convenient method of obtaining prothrombin time (INR) test results, enabling patient counseling and medication dosage adjustments at the time of the visit.
  • Systematic anticoagulation management leads to improved patient outcomes and lower costs associated with adverse events, enhancing patient satisfaction.
  • DuPont Pharmaceuticals is a worldwide business focusing on research, development, and delivery of pharmaceuticals and imaging products to treat unmet medical needs.
  • The company operates in 70 countries and has 94,000 employees.

Statistics:

  • The agreement is for a five-year period.
  • 936,000 employees work for DuPont.
  • In 1802, the company was founded.
  • The Roche Group operates in the fields of pharmaceuticals, diagnostics, and vitamins.
  • The most common adverse event and serious risk of oral anticoagulation therapy with Coumadin(R) is bleeding in any tissue or organ.

Sources:

  • PRNewswire (Dec. 6)